45 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
II. Discovery of a novel series of CXCR3 antagonists with a beta amino acid core.
Sanofi
I. Discovery of a novel series of CXCR3 antagonists. Multiparametric optimization of N,N-disubstituted benzylamines.
Sanofi
N-Arylsulfonyl-a-amino carboxamides are potent and selective inhibitors of the chemokine receptor CCR10 that show efficacy in the murine DNFB model of contact hypersensitivity.
Boehringer Ingelheim Pharmaceuticals
Discovery and Characterization of Biased Allosteric Agonists of the Chemokine Receptor CXCR3.
Friedrich-Alexander University
IV. Discovery of CXCR3 antagonists substituted with heterocycles as amide surrogates: improved PK, hERG and metabolic profiles.
Merck Research Laboratories
Exploring a pocket for polycycloaliphatic groups in the CXCR3 receptor with the aid of a modular synthetic strategy.
Vu University Amsterdam
CXCR3 antagonists: quaternary ammonium salts equipped with biphenyl- and polycycloaliphatic-anchors.
Vu University Amsterdam
Chemical subtleties in small-molecule modulation of peptide receptor function: the case of CXCR3 biaryl-type ligands.
Vu University Amsterdam
Lead identification of 2-iminobenzimidazole antagonists of the chemokine receptor CXCR3.
Abbott Bioresearch Center
Development of CXCR3 antagonists. Part 4: discovery of 2-amino-(4-tropinyl)quinolines.
Ucb Pharma
Discovery of small molecule benzimidazole antagonists of the chemokine receptor CXCR3.
Abbott Bioresearch Center
Discovery and optimization of a series of quinazolinone-derived antagonists of CXCR3.
Amgen
III. Identification of novel CXCR3 chemokine receptor antagonists with a pyrazinyl-piperazinyl-piperidine scaffold.
Merck Research Laboratories
Special ergolines efficiently inhibit the chemokine receptor CXCR3 in blood.
Novartis Institutes For Biomedical Research
II. SAR studies of pyridyl-piperazinyl-piperidine derivatives as CXCR3 chemokine antagonists.
Ligand Pharmaceuticals
Identification of a new class of small molecule C5a receptor antagonists.
Wyeth Research
Special ergolines are highly selective, potent antagonists of the chemokine receptor CXCR3: discovery, characterization and preliminary SAR of a promising lead.
Novartis Institutes For Biomedical Research
Synthesis and structure-activity relationship of benzetimide derivatives as human CXCR3 antagonists.
Johnson & Johnson Prd
Camphor sulfonamide derivatives as novel, potent and selective CXCR3 antagonists.
Glaxosmithkline
Optimization of the heterocyclic core of the quinazolinone-derived CXCR3 antagonists.
Amgen
Development of CXCR3 antagonists. Part 3: Tropenyl and homotropenyl-piperidine urea derivatives.
Ucb Pharma
Development of CXCR3 antagonists. Part 2: Identification of 2-amino(4-piperidinyl)azoles as potent CXCR3 antagonists.
Ucb Pharma
Structural Analysis of Chemokine Receptor-Ligand Interactions.
Vrije Universiteit Amsterdam
Discovery of Clinical Candidate ACT-777991, a Potent CXCR3 Antagonist for Antigen-Driven and Inflammatory Pathologies.
Idorsia Pharmaceuticals
Identification and structure-activity relationships of 1-aryl-3-piperidin-4-yl-urea derivatives as CXCR3 receptor antagonists.
Ucb Pharma
Identification and initial evaluation of 4-N-aryl-[1,4]diazepane ureas as potent CXCR3 antagonists.
Pharmacopeia Drug Discovery
Design, Synthesis, and Pharmacological Evaluation of Benzimidazolo-thiazoles as Potent CXCR3 Antagonists with Therapeutic Potential in Autoimmune Diseases: Discovery of ACT-672125.
Idorsia Pharmaceuticals
Synthesis and structure-activity relationship of 3-phenyl-3H-quinazolin-4-one derivatives as CXCR3 chemokine receptor antagonists.
Vrije Universiteit Amsterdam
Synthesis and structure-activity relationships of indazole arylsulfonamides as allosteric CC-chemokine receptor 4 (CCR4) antagonists.
Glaxosmithkline
Discovery of Novel 1-Cyclopentenyl-3-phenylureas as Selective, Brain Penetrant, and Orally Bioavailable CXCR2 Antagonists.
Gsk Pharmaceuticals R & D
Design, synthesis and evaluation of new thiazole-piperazines as acetylcholinesterase inhibitors.
Anadolu University
An Isochemogenic Set of Inhibitors To Define the Therapeutic Potential of Histone Deacetylases in ß-Cell Protection.
Broad Institute of Harvard and Mit
Derivatives form better lipoxygenase inhibitors than piperine: in vitro and in silico study.
Kannur University, Thalassery Campus
Trypanocidal bisbenzylisoquinoline alkaloids are inhibitors of trypanothione reductase.
Orstom